FLEMINGTON, N.J., June 24 /PRNewswire/ -- Beardsworth Consulting Group, Inc. announces the appointments of Alison Martin, M.D. as the company's Scientific Advisor, Oncology and Robert W. Malone, M.D. as the company's Medical Director, Vaccines.
Dr. Alison Martin is one of oncology's respected research leaders with over 20 years of clinical research experience. She joins Beardsworth from the National Cancer Institute (NCI) where she was most recently Head of Genitourinary Cancers and Melanoma Therapeutics in the Clinical Investigations Branch of the Cancer Therapy Evaluation Program (CTEP). Dr. Martin was scientific co-chair along with Dr. Meenhard Herlyn of the 2007 NCI-Community-Oriented Strategic Action Plan for Melanoma Research. She has served as liaison to three of NCI's cooperative groups and been a senior investigator in the Investigational Drug Branch of CTEP. In addition to experience at NCI, Dr. Martin was a team leader in the Office of Oncology Drug Products at the U.S. Food and Drug Administration and has experience working with the biotechnology and pharmaceutical industries.
Dr. Robert Malone has extensive experience in viral and recombinant vaccines, biodefense, gene delivery and transfer, immunology, tissue and cell culture, and DNA vaccination in both the commercial and government market sectors. An internationally recognized scientist, Dr. Malone is known as one of the original inventors of "DNA Vaccination" holding numerous fundamental domestic & foreign patents in the fields of gene delivery, delivery formulations, and vaccines. His background includes over 25 years of experience in academia and industry, including both founding and wor
|SOURCE Beardsworth Consulting Group, Inc.|
Copyright©2010 PR Newswire.
All rights reserved